Taro Pharmaceuticals U.s.a., Inc.
Taro Pharmaceuticals U.s.a., Inc. (United States) is linked to 1 FDA-registered manufacturing site. 44 FDA enforcement records are linked to it.
Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records
Cite as: PharmaTek, “Taro Pharmaceuticals U.s.a., Inc.: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/taro-pharmaceuticals-u-s-a-inc
Overview
Taro Pharmaceuticals U.s.a., Inc. is a pharmaceutical company headquartered in Hawthorne, United States.
Registered manufacturing sites (1)
Physical sites registered with the US FDA and resolved to Taro Pharmaceuticals U.s.a., Inc., with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.
FDA compliance signals
44 FDA enforcement records linked to this company.
- recall — Class III2024-08-21
Failed Impurities/Degradation Specifications: Out-of-specification results obtained for related impurities and slightly lower than the established level of the Hydrocortisone Assay obtained during stability testing.
- recall — Class III2022-04-06
Failed Content Uniformity Specifications: Out-of-specification result for the Betamethasone Dipropionate assay of a stability sample
- recall — Class I2022-01-19
Microbial Contamination of Non-Sterile Products: presence of R. Pickettii bacteria
- recall — Class II2021-02-10
CGMP deviations.
- recall — Class II2020-12-23
Failed Impurities/Degradation Specifications: An unknown degradation impurity was detected slightly above the specification limit in Clotrimazole Cream USP 1%.
- recall — Class II2020-12-23
Failed Impurities/Degradation Specifications: An unknown degradation impurity was detected slightly above the specification limit in Clotrimazole Cream USP 1%.
- recall — Class II2020-12-23
Failed Impurities/Degradation Specifications: An unknown degradation impurity was detected slightly above the specification limit in Clotrimazole Cream USP 1%.
- recall — Class II2020-12-23
Failed Impurities/Degradation Specifications: An unknown degradation impurity was detected slightly above the specification limit in Clotrimazole Cream USP 1%.
- recall — Class II2020-12-23
Failed Impurities/Degradation Specifications: An unknown degradation impurity was detected slightly above the specification limit in Clotrimazole Cream USP 1%.
- recall — Class II2020-12-23
Failed Impurities/Degradation Specifications: An unknown degradation impurity was detected slightly above the specification limit in Clotrimazole Cream USP 1%.
- recall — Class II2020-12-23
Failed Impurities/Degradation Specifications: An unknown degradation impurity was detected slightly above the specification limit in Clotrimazole Cream USP 1%.
- recall — Class II2020-12-23
Failed Impurities/Degradation Specifications: An unknown degradation impurity was detected slightly above the specification limit in Clotrimazole Cream USP 1%.
- recall — Class II2020-12-23
Failed Impurities/Degradation Specifications: An unknown degradation impurity was detected slightly above the specification limit in Clotrimazole Cream USP 1%.
- recall — Class II2020-12-23
Failed Impurities/Degradation Specifications: An unknown degradation impurity was detected slightly above the specification limit in Clotrimazole Cream USP 1%.
- recall — Class III2020-08-19
Failed Content Uniformity: bulk lot used to make these two lots was found to have failed content uniformity.
- recall — Class I2020-03-04
Resuspension Problems: Two lots of Phenytoin Oral Suspension USP 125mg/5mL may coagulate and may not resuspend as per the label copy instructions.
- recall — Class I2020-02-19
Cross Contamination; Lamotrigine Tablets 100 mg USP was contaminated with enalapril maleate.
- recall — Class II2019-11-06
Presence of Foreign Substance: Ibuprofen Oral Suspension USP may have small particles of an inert plastic material introduced during manufacturing.
- recall — Class II2019-11-06
Presence of Foreign Substance: Ibuprofen Oral Suspension USP may have small particles of an inert plastic material introduced during manufacturing.
- recall — Class II2019-11-06
Presence of Foreign Substance: Ibuprofen Oral Suspension USP may have small particles of an inert plastic material introduced during manufacturing.
- recall — Class II2019-11-06
Presence of Foreign Substance: Ibuprofen Oral Suspension USP may have small particles of an inert plastic material introduced during manufacturing.
- recall — Class II2019-11-06
Presence of Foreign Substance: Ibuprofen Oral Suspension USP may have small particles of an inert plastic material introduced during manufacturing.
- recall — Class II2018-11-21
Failed Impurities/Degradation Specifications: unknown impurity higher than the specified limit was detected during routine stability testing.
- recall — Class II2018-11-21
Failed Impurities/Degradation Specifications: unknown impurity higher than the specified limit was detected during routine stability testing.
- recall — Class II2018-11-21
Failed Impurities/Degradation Specifications: unknown impurity higher than the specified limit was detected during routine stability testing.
- recall — Class III2018-02-07
Failed Content Uniformity Specifications
- recall — Class III2017-11-01
Cross contamination with other products: traces of Dapsone were found in the finished product.
- recall — Class III2017-05-24
Cross contamination with other products: Certain lots of Fluocinonide Cream were found to be contaminated with a small quantity of hydrocortisone-17-valerate.
- recall — Class II2017-04-26
Failed Content Uniformity Specifications; out-of-specification (OOS) results 18-month stability
- recall — Class III2016-11-16
Subpotent Drug: Out of Specification assay values on stability for the active ingredient, zinc pyrithione.
- recall — Class III2016-06-08
Subpotent Drug
- recall — Class II2015-02-11
Presence of Foreign Substance: Presence of blue plastic floating in loratadine syrup.
- recall — Class III2014-11-05
Marketed without an Approved NDA/ANDA: One lot was on hold-pending release status when it was erroneously made available for sale in the inventory control system. An alternate manufacturing site for the Carbamazepine API final intermediate was pending approval.
- recall — Class III2014-09-24
Failed Content Uniformity Specifications.
- recall — Class III2013-12-18
Subpotent. drug
- 4832013-04-18
Complaint Handling Procedure
- 4832013-04-18
Failure to develop written procedures
- 4832013-04-18
Failure by applicant to report ADE
- recall — Class II2012-12-12
Product Lacks Stability: Out-of-specification (OOS) results were observed for assay and description in retain samples.
- 4832012-03-08
Late submission of 15-day report
- 4832012-03-08
Wrong form - domestic ADE
- 4832009-05-29
Failure to review ADE information
- 4832009-05-29
Late submission of quarterly safety reports
- 4832009-05-29
Late submission of 15-day report
Is this Taro Pharmaceuticals U.s.a., Inc.?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.
Need suppliers found and checked?
The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.